Recent advances and limitations in the application of kahalalides for the control of cancer

Scott Wyer, Danyelle M. Townsend, Zhiwei Ye, Antonis Kourtidis, Yeun Mun Choo, André Luís Branco de Barros, Mohamed S. Donia, Mark T. Hamann

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Since the discovery of the kahalalide family of marine depsipeptides in 1993, considerable work has been done to develop these compounds as new and biologically distinct anti-cancer agents. Clinical trials and laboratory research have yielded a wealth of data that indicates tolerance of kahalalides in healthy cells and selective activity against diseased cells. Currently, two molecules have attracted the greates level of attention, kahalalide F (KF) and isokahalalide F (isoKF, Irvalec, PM 02734, elisidepsin). Both compounds were originally isolated from the sarcoglossan mollusk Elysia rufescens but due to distinct structural characteristics it has been hypothesized and recently shown that the ultimate origin of the molecules is microbial. The search for their true source has been a subject of considerable research in the anticipation of finding new analogs and a culturable expression system that can produce sufficient material through fermentation to be industrially relevant.

Original languageEnglish (US)
Article number112676
JournalBiomedicine and Pharmacotherapy
StatePublished - Apr 2022

All Science Journal Classification (ASJC) codes

  • Pharmacology


  • 16SrRNA
  • Akt
  • Anti-psoriatic
  • Bryopsis
  • Cancer
  • Cytochrome c oxidase I
  • Cytotoxicity
  • Depsipeptide
  • Elisidepsin
  • ErbB
  • Her2
  • Her3
  • Isokahalalide
  • Kahalalide
  • Kahalalide A
  • Kahalalide G
  • MAPK
  • Mollusk
  • Oncosis


Dive into the research topics of 'Recent advances and limitations in the application of kahalalides for the control of cancer'. Together they form a unique fingerprint.

Cite this